American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Autor: Joseph D. Feuerstein, Geoffrey C. Nguyen, Sonia S. Kupfer, Yngve Falck-Ytter, Siddharth Singh, Lauren Gerson, Ikuo Hirano, Joel H. Rubenstein, Walter E. Smalley, Neil Stollman, Shahnaz Sultan, Santhi S. Vege, Sachin B. Wani, David Weinberg, Yu-Xiao Yang
Rok vydání: 2017
Předmět:
medicine.medical_specialty
Consensus
Treatment outcome
Anti-Inflammatory Agents
MEDLINE
Inflammatory bowel disease
law.invention
03 medical and health sciences
0302 clinical medicine
Gastrointestinal Agents
Randomized controlled trial
Predictive Value of Tests
law
Internal medicine
medicine
Humans
030212 general & internal medicine
Intensive care medicine
Societies
Medical
6-Thioguanine
Evidence-Based Medicine
Hepatology
medicine.diagnostic_test
Thiopurine methyltransferase
biology
business.industry
Gastroenterology
Guideline
Inflammatory Bowel Diseases
medicine.disease
United States
digestive system diseases
Surgery
Editorial
Treatment Outcome
Therapeutic drug monitoring
030220 oncology & carcinogenesis
Pediatrics
Perinatology and Child Health
biology.protein
030211 gastroenterology & hepatology
Drug Monitoring
business
Zdroj: Gastroenterology. 153:827-834
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2017.07.032
Popis: The recently published American Gastroenterological Association (AGA) guideline on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) provides important and useful perspectives for individuals caring for and managing individuals with IBD and also for researchers focusing on this area (1). The guideline reviews key aspects of the roles that TDM increasingly has in the management of individuals with IBD and highlights key concepts. It also illustrates that many of these areas are supported by scanty evidence. Consequently, this also serves to prompt further study that might expand the evidence base accordingly.
Databáze: OpenAIRE
Externí odkaz: